UA117685C2 - Складена композиція для перорального введення, яка містить езетиміб та розувастатин - Google Patents

Складена композиція для перорального введення, яка містить езетиміб та розувастатин

Info

Publication number
UA117685C2
UA117685C2 UAA201605792A UAA201605792A UA117685C2 UA 117685 C2 UA117685 C2 UA 117685C2 UA A201605792 A UAA201605792 A UA A201605792A UA A201605792 A UAA201605792 A UA A201605792A UA 117685 C2 UA117685 C2 UA 117685C2
Authority
UA
Ukraine
Prior art keywords
ezetimibe
rosuvastatin
composite formulation
oral administration
particle size
Prior art date
Application number
UAA201605792A
Other languages
English (en)
Inventor
Чун Х'юн Чхо
Чін Чхел Кім
Йон Іль Кім
Син Чун Лі
Че Х'юн Парк
Чон Су Ву
Original Assignee
Ханмі Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53791740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117685(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ханмі Фарм. Ко., Лтд. filed Critical Ханмі Фарм. Ко., Лтд.
Publication of UA117685C2 publication Critical patent/UA117685C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується твердої складеної композиції для перорального введення, яка містить частину, що складається з гранул езетимібу, яка містить езетиміб і має гранулометричний склад із середнім розміром частинок d(0,9) для 90 % нижньої фракції, що складає приблизно 10 мкм або менше; та частину, що складається із суміші розувастатину, яка містить розувастатин або його фармацевтично прийнятну сіль. Також винахід стосується способу отримання цієї складеної композиції.
UAA201605792A 2013-12-30 2014-12-30 Складена композиція для перорального введення, яка містить езетиміб та розувастатин UA117685C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130167156 2013-12-30
KR1020140071081A KR20150079373A (ko) 2013-12-30 2014-06-11 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
PCT/KR2014/013087 WO2015102400A1 (en) 2013-12-30 2014-12-30 Composite formulation for oral administration comprising ezetimibe and rosuvastatin

Publications (1)

Publication Number Publication Date
UA117685C2 true UA117685C2 (uk) 2018-09-10

Family

ID=53791740

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201605792A UA117685C2 (uk) 2013-12-30 2014-12-30 Складена композиція для перорального введення, яка містить езетиміб та розувастатин

Country Status (25)

Country Link
US (1) US10434067B2 (uk)
EP (1) EP3089739A4 (uk)
JP (1) JP2017500303A (uk)
KR (2) KR20150079373A (uk)
CN (1) CN105873571B (uk)
AR (1) AR098996A1 (uk)
AU (1) AU2014374552B2 (uk)
CA (1) CA2933178A1 (uk)
CL (1) CL2016001654A1 (uk)
CR (1) CR20160293A (uk)
DO (1) DOP2016000159A (uk)
GT (1) GT201600137A (uk)
MX (1) MX2016008725A (uk)
MY (1) MY187637A (uk)
NI (1) NI201600093A (uk)
PE (1) PE20161072A1 (uk)
PH (1) PH12016501196A1 (uk)
RU (1) RU2683937C2 (uk)
SG (1) SG10201805657PA (uk)
SV (1) SV2016005236A (uk)
TW (1) TWI655944B (uk)
UA (1) UA117685C2 (uk)
UY (1) UY35932A (uk)
WO (1) WO2015102400A1 (uk)
ZA (1) ZA201603934B (uk)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180069068A (ko) * 2015-10-30 2018-06-22 캔서 프리벤션 파마수티컬스, 인코포레이티드 에플로르니틴 및 설린닥, 고정된 용량 조합 제제
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
JP2017210455A (ja) * 2016-05-27 2017-11-30 ニプロ株式会社 エゼチミブ含有医薬組成物
CZ2016539A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
CZ2016538A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky
KR101910902B1 (ko) * 2016-11-03 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
KR102206535B1 (ko) * 2016-11-29 2021-01-22 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
JP6848469B2 (ja) * 2017-01-20 2021-03-24 ニプロ株式会社 エゼチミブ含有医薬組成物の製造方法
JP7115825B2 (ja) * 2017-06-28 2022-08-09 日医工株式会社 エゼチミブ含有経口製剤及びその製造方法
JP2019014700A (ja) * 2017-07-11 2019-01-31 大原薬品工業株式会社 エゼチミブ含有口腔内崩壊錠及びその製造方法
JP6937195B2 (ja) * 2017-09-01 2021-09-22 興和株式会社 医薬組成物
KR102569271B1 (ko) * 2018-03-19 2023-08-23 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 약제학적 복합제제
GR1009727B (el) * 2018-11-28 2020-04-14 Elpen Αε Φαρμακευτικη Βιομηχανια Μονολιθικη σταθερη φαρμακοτεχνικη μορφη ταχειας αποδεσμευσης εζετιμιμπης και ροσουβαστατινης
WO2021019499A1 (en) 2019-07-31 2021-02-04 TECNIMEDE - Sociedade Técnico-medicinal, SA Solid oral multiple-unit immediate release compositions, methods and uses thereof
BR112023003323A2 (pt) * 2020-08-25 2023-03-21 Daewoong Pharmaceutical Co Ltd Composição farmacêutica em forma de dosagem única
CN112999178A (zh) * 2021-03-01 2021-06-22 乐普制药科技有限公司 一种依折麦布匹伐他汀钙复方双层片剂
GB2622822A (en) * 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
ES2154277T3 (es) 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
HUP0302269A3 (en) 2000-12-20 2009-08-28 Schering Corp Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU2002247019C1 (en) 2001-01-26 2017-05-11 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
JP2005501861A (ja) 2001-08-22 2005-01-20 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング １，４−ベンゾチエピン１，１−ジオキシド誘導体と他の活性物質との組合わせ剤及びそれらの使用
WO2005011586A2 (en) 2003-07-28 2005-02-10 Dr. Reddy's Laboratories, Inc. Treatment and preventi0n of cardiovascular events
EP1865947A1 (en) 2005-04-04 2007-12-19 Pontificia Universidad Catolica de Chile The use of ezetimibe in the prevention and treatment of cholesterol gallstones
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
EA017349B1 (ru) 2007-01-24 2012-11-30 Крка Способ получения эзетимиба и его производных
EP2120882A2 (en) * 2007-02-23 2009-11-25 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
WO2009016358A2 (en) 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
JP5566288B2 (ja) * 2008-05-30 2014-08-06 武田薬品工業株式会社 複素環化合物
CA2728539A1 (en) 2008-06-27 2009-12-30 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
ATE536172T1 (de) * 2009-03-13 2011-12-15 Sanovel Ilac Sanayi Ve Ticaret As Ezetimibzusammensetzungen
US20110196383A1 (en) 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
EP2448919A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
WO2011139256A2 (en) * 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
WO2013066279A1 (en) * 2011-10-13 2013-05-10 Mahmut Bilgic Solid dosage forms comprising ezetimibe
PL2844233T3 (pl) * 2012-05-01 2020-09-07 Althera Life Sciences, Llc Preparat w postaci tabletki do stosowania doustnego składający się ze stałego połączenia rosuwastatyny i ezetymibu w leczeniu hiperlipidemii i chorób sercowo-naczyniowych
ES2905251T3 (es) * 2012-05-22 2022-04-07 Kuhnil Pharm Co Ltd Forma de recubrimiento multicapa de composición farmacéutica administrada por vía oral que contiene ácido graso omega-3 o éster alquílico del mismo y fármaco a base de estatina
MX2012014970A (es) * 2012-12-18 2013-08-27 Hetlabs Mexico S A De C V Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso.
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형

Also Published As

Publication number Publication date
EP3089739A4 (en) 2017-08-02
RU2016123828A3 (uk) 2018-08-28
CA2933178A1 (en) 2015-07-09
SV2016005236A (es) 2016-11-03
UY35932A (es) 2015-07-31
TW201609091A (zh) 2016-03-16
EP3089739A1 (en) 2016-11-09
KR20150079454A (ko) 2015-07-08
CL2016001654A1 (es) 2017-01-06
PH12016501196B1 (en) 2016-08-15
WO2015102400A1 (en) 2015-07-09
MY187637A (en) 2021-10-05
TWI655944B (zh) 2019-04-11
RU2016123828A (ru) 2018-02-07
AR098996A1 (es) 2016-06-22
CR20160293A (es) 2016-10-05
SG10201805657PA (en) 2018-08-30
US10434067B2 (en) 2019-10-08
GT201600137A (es) 2018-10-19
PH12016501196A1 (en) 2016-08-15
MX2016008725A (es) 2017-02-28
DOP2016000159A (es) 2016-12-15
AU2014374552B2 (en) 2019-09-19
CN105873571A (zh) 2016-08-17
AU2014374552A1 (en) 2016-06-02
PE20161072A1 (es) 2016-11-04
ZA201603934B (en) 2017-09-27
RU2683937C2 (ru) 2019-04-03
US20160346213A1 (en) 2016-12-01
NI201600093A (es) 2016-07-22
JP2017500303A (ja) 2017-01-05
KR20150079373A (ko) 2015-07-08
CN105873571B (zh) 2019-10-22

Similar Documents

Publication Publication Date Title
UA117685C2 (uk) Складена композиція для перорального введення, яка містить езетиміб та розувастатин
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2015009785A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
SG10201804817TA (en) Delayed release compositions of linaclotide
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
SG10201811586YA (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
WO2014114255A3 (zh) 一种定位速释生物粘附剂及应用
WO2017103600A8 (en) Preparation of respirable zafirlukast particles
SI3003383T1 (sl) Trdni sestavek za oralno dajanje, ki vsebuje ibandronsko kislino ali njeno farmacevtsko sprejemljivo sol, in vitamin D
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
EP3648745A4 (en) PHARMACEUTICAL COMPOSITION CONSISTING OF A MULTI-UNIT SPHEROIDAL TABLET CONTAINING ESOMEPRAZOLE AND A PHARMACEUTICAL SALT OF THE SAME, AND PROCESS FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITION
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
IN2013MU01177A (uk)
AU2014226192A8 (en) Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
MY181226A (en) Formulation of metaxalone
PH12016502540A1 (en) Pharmaceutical dosage forms
WO2016187595A3 (en) Oral pharmaceutical composition of methylergonovine
NZ728386A (en) Use of phthalide compound
UA80535U (uk) Фармацевтична композиція для лікування сексуальної дисфункції